WO2006128679A3 - Phosphatidylinositol composition and 3'-phosphorylated lysophosphatidylinositols in the treatment of cancer and autoimmune diseases - Google Patents

Phosphatidylinositol composition and 3'-phosphorylated lysophosphatidylinositols in the treatment of cancer and autoimmune diseases Download PDF

Info

Publication number
WO2006128679A3
WO2006128679A3 PCT/EP2006/005159 EP2006005159W WO2006128679A3 WO 2006128679 A3 WO2006128679 A3 WO 2006128679A3 EP 2006005159 W EP2006005159 W EP 2006005159W WO 2006128679 A3 WO2006128679 A3 WO 2006128679A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
phosphorylated
phosphatidylinositol
treatment
tumorous
Prior art date
Application number
PCT/EP2006/005159
Other languages
French (fr)
Other versions
WO2006128679A2 (en
Inventor
Martin Andreas Thurnher
Thomas Putz
Original Assignee
Martin Andreas Thurnher
Thomas Putz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martin Andreas Thurnher, Thomas Putz filed Critical Martin Andreas Thurnher
Priority to EP06753989A priority Critical patent/EP1885385A2/en
Publication of WO2006128679A2 publication Critical patent/WO2006128679A2/en
Publication of WO2006128679A3 publication Critical patent/WO2006128679A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to a combination or a combination compound comprising a 31-phosphorylated form of phosphatidylinositol and a secretory (s) phospholipase A2. Also provided are pharmaceutical compositions comprising 3'-phosphorylated lyso-phosphatidylinositols. Furthermore, the invention relates to a pharmaceutical composition comprising the combination or combination compound of the invention. Moreover, the present invention provides for the use of a combination or a combination compound of the invention, for a preparation of a pharmaceutical composition for the treatment of a proliferative disorder and/or tumorous disease. Moreover, the present invention provides for a method for the generation of a cellular lysate of normal or tumorous/tumor cells comprising the steps of: (a) contacting non-tumorous cells or tumorous/tumor cells with the combination or combination compound of the invention; and (b) obtaining the resulting cellular lysate.
PCT/EP2006/005159 2005-05-31 2006-05-30 Phosphatidylinositol composition and 3'-phosphorylated lysophosphatidylinositols in the treatment of cancer and autoimmune diseases WO2006128679A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06753989A EP1885385A2 (en) 2005-05-31 2006-05-30 Phosphatidylinositol combination composition and 3'-phosphorylated lysophosphatidylinositols in the treatment of cancer and autoimmune diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05011714 2005-05-31
EP05011714.2 2005-05-31

Publications (2)

Publication Number Publication Date
WO2006128679A2 WO2006128679A2 (en) 2006-12-07
WO2006128679A3 true WO2006128679A3 (en) 2007-02-22

Family

ID=37309513

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/005159 WO2006128679A2 (en) 2005-05-31 2006-05-30 Phosphatidylinositol composition and 3'-phosphorylated lysophosphatidylinositols in the treatment of cancer and autoimmune diseases

Country Status (2)

Country Link
EP (1) EP1885385A2 (en)
WO (1) WO2006128679A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2654631A1 (en) * 2006-06-09 2007-12-13 Erasmus University Medical Center Rotterdam Modulation of the immune system by inositol phospholipids
CN101686986A (en) * 2006-12-29 2010-03-31 诺尔姆奥克西斯公司 cyclitols and their derivatives and their therapeutic applications

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023760A1 (en) * 1996-11-25 1998-06-04 Icos Corporation Phosphatidylinositol 3-kinase p110 delta catalytic subunit
WO2002004522A2 (en) * 2000-07-10 2002-01-17 Novartis Ag Bifunctional molecules and vectors complexed therewith for targeted gene delivery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023760A1 (en) * 1996-11-25 1998-06-04 Icos Corporation Phosphatidylinositol 3-kinase p110 delta catalytic subunit
WO2002004522A2 (en) * 2000-07-10 2002-01-17 Novartis Ag Bifunctional molecules and vectors complexed therewith for targeted gene delivery

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PUTZ T ET AL: "Antitumor action and immune activation through cooperation of bee venom secretory phospholipase A2 and phosphatidylinositol-(3,4)-bisph osphate", CANCER IMMUNOLOGY, IMMUNOTHERAPY 2006 GERMANY, vol. 55, no. 11, 2006, pages 1374 - 1383, XP002407388, ISSN: 0340-7004 *
PUTZ T. ET AL.: "Bee venom secretory phospholipase and phosphatidylinositol-homologues cooperatively disrupt membrane integrity, abrogate signal transduction and inhibit proliferation of renal cancer cells", CANCER IMMUNOL. IMMUNOTHER., XP002407389, Retrieved from the Internet <URL:http://www.springerlink.com/content/w550pj65437v2v65/fulltext.pdf> [retrieved on 20061114] *
RAMONER R ET AL: "Dendritic-cell activation by secretory phospholipase A2", BLOOD 01 MAY 2005 UNITED STATES, vol. 105, no. 9, 1 May 2005 (2005-05-01), pages 3583 - 3587, XP002407390, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
WO2006128679A2 (en) 2006-12-07
EP1885385A2 (en) 2008-02-13

Similar Documents

Publication Publication Date Title
WO2006099169A3 (en) Novel liposome compositions
WO2006020048A3 (en) Compounds and methods for treatment of cancer
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
WO2006029176A3 (en) Cancer-testis antigens
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
WO2010078421A8 (en) Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds
WO2006058868A3 (en) Substituted pteridines for treating inflammatory diseases
WO2005062977A3 (en) Prostate cancer specific internalizing human antibodies
WO2005113747A3 (en) Multicellular tissue and organ culture systems
EP1712235A3 (en) Combinational therapy involving a small molecule inhibitor of the MDM2: P53 interaction
WO2006055352A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
WO2006097743A3 (en) Method for actvating natural killer cells by tumor cell preparation in vitro
WO2007075921A3 (en) De-n-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
TW200731987A (en) Cytotoxicity mediation of cells evidencing surface expression of CD44
WO2002074237A8 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
WO2005089294A3 (en) Synthesis of indenoisoquinoliniums and methods of use
WO2007027344A3 (en) Compounds and methods for the treatment of cancer
WO2007095729A8 (en) Cytotoxicity mediation of cells evidencing surface expression of cd63
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
WO2000066528A3 (en) Quinones for treatment of diseases
WO2008118733A3 (en) Methods of treating cancer by administering human il-18 combinations
WO2006081445A3 (en) Treatment of metastasized tumors
WO2005065361A3 (en) Compounds and compositions for treating dysproliferative diseases, and methods of use thereof
EP1667716B8 (en) Cytotoxicity mediation of cells evidencing surface expression of cd44

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006753989

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2006753989

Country of ref document: EP